mTOR in Human Diseases

Guest Editor:

Dr. Olivier Dormond
Department of Visceral Surgery,
Lausanne University Hospital,
Pavillon 4, Avenue de Beaumont,
1011 Lausanne, Switzerland
olivier.dormond@chuv.ch

Deadline for manuscript submissions:
10 January 2019

Message from the Guest Editor

Dear Colleagues,

The mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that is ubiquitously expressed. It represents a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, mTOR regulates a variety of cellular processes including protein, lipid and nucleotide synthesis as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified. It is therefore important to further fully investigate mTOR signaling at a molecular level in order to identify additional clinical opportunities of targeting mTOR in human disorders. This Special Issue of “mTOR in Human Diseases” will cover a selection of research articles related to mTOR in human pathologies. Emphasis will be given to the molecular aspects of mTOR in specific conditions. Experimental studies, review articles and commentaries are all welcome.

Dr. Olivier Dormond
Guest Editor

mdpi.com/si/10792